What are the recommended next steps in management for a patient with CT findings of cirrhotic liver morphology, portal hypertension (prominent splenorenal collateral veins and suboptimally assessed portal vein), a 3‑mm non‑obstructing left renal calculus, and distal colonic diverticulosis without diverticulitis?

Management of Cirrhosis with Portal Hypertension

This patient requires comprehensive hepatology evaluation with focus on variceal screening, assessment of hepatic decompensation risk, and initiation of portal pressure-lowering therapy if clinically significant portal hypertension is confirmed. The CT findings reveal cirrhosis with evidence of portal hypertension (splenorenal collaterals), which fundamentally changes management priorities toward preventing life-threatening complications like variceal hemorrhage.

Immediate Priority: Variceal Screening and Risk Stratification

The presence of cirrhotic morphology with portal hypertension indicators (splenorenal collaterals) mandates urgent evaluation for esophagogastric varices, as these carry significant mortality risk if they rupture 1, 2. Upper endoscopy (esophagogastroduodenoscopy) should be performed to screen for varices, as clinically significant portal hypertension (CSPH) is likely present given the imaging findings 3.

Key Actions:

• Schedule upper endoscopy to identify and grade any esophageal or gastric varices
• If high-risk varices are found, initiate non-selective beta-blocker therapy (propranolol or carvedilol) for primary prophylaxis against variceal bleeding 2, 3
• Consider hepatic venous pressure gradient (HVPG) measurement if available, as HVPG ≥10 mmHg defines CSPH and guides therapy 1

Portal Vein Assessment

The CT report specifically notes suboptimal portal vein evaluation on arterial phase imaging. Obtain a dedicated multiphase CT abdomen or MRI with venous phase imaging to fully assess portal vein patency 1. This is critical because:

• Portal vein thrombosis occurs in 10-25% of cirrhotic patients and dramatically alters management
• Distinguishing bland thrombus from tumor thrombus (hepatocellular carcinoma) is essential
• Portal vein patency affects candidacy for transjugular intrahepatic portosystemic shunt (TIPS) if needed

Hepatocellular Carcinoma Surveillance

Initiate HCC surveillance with ultrasound ± AFP every 6 months, as cirrhotic patients have 1-6% annual HCC incidence 4. While the current CT showed no suspicious lesions, dedicated surveillance imaging is mandatory. If ultrasound quality is poor (common in cirrhosis), use multiphase CT or MRI for surveillance.

Assessment of Hepatic Decompensation

Evaluate for signs of decompensation that may not be apparent on imaging alone 1, 5:

• Check for ascites clinically (physical exam, consider diagnostic paracentesis if present)
• Assess for hepatic encephalopathy (clinical evaluation, consider lactulose/rifaximin if present)
• Laboratory evaluation: Complete metabolic panel, CBC (thrombocytopenia suggests hypersplenism from portal hypertension), INR, albumin, bilirubin
• Calculate MELD-Na score to assess transplant candidacy and prognosis
• Screen for spontaneous bacterial peritonitis if ascites is present

The presence of portal hypertension with collaterals indicates this patient is at high risk for decompensation, with 5-year survival dropping from 80% (compensated) to 50% (decompensated) 1.

Hepatology Referral

Refer to hepatology immediately for:

• Determination of cirrhosis etiology (if not already established)
• Liver transplant evaluation if decompensated or MELD-Na ≥15
• Management of portal hypertension complications
• Consideration for clinical trials or advanced therapies

Management of Incidental Findings

Renal Calculus (3 mm, non-obstructing)

• No intervention required for asymptomatic 3 mm stone
• Ensure adequate hydration
• Counsel on stone prevention (dietary modifications)
• Repeat imaging only if symptoms develop

Diverticulosis

• No specific intervention needed in absence of diverticulitis
• High-fiber diet counseling
• Educate on diverticulitis warning signs
• Caution: If variceal bleeding occurs, avoid NSAIDs for pain management as they increase bleeding risk and can precipitate hepatorenal syndrome 6

Common Pitfalls to Avoid

1. Do not delay endoscopy: Waiting for "complete workup" before variceal screening can be fatal if bleeding occurs
2. Do not assume portal vein is patent: The suboptimal assessment must be clarified with proper imaging
3. Do not use NSAIDs: These worsen portal hypertension, increase bleeding risk, and precipitate renal failure in cirrhosis
4. Do not overlook nutrition: Assess for sarcopenia and malnutrition, which worsen outcomes 5
5. Do not forget vaccinations: Ensure hepatitis A/B, pneumococcal, and annual influenza vaccines are current

Monitoring Strategy

• Endoscopic surveillance: Repeat every 1-3 years depending on initial findings and presence of varices
• HCC surveillance: Every 6 months indefinitely
• Clinical follow-up: Every 3-6 months with hepatology to monitor for decompensation
• Laboratory monitoring: Every 3-6 months (CBC, CMP, INR, AFP)

The finding of portal hypertension fundamentally shifts this patient from potential compensated cirrhosis to high-risk status requiring intensive monitoring and prophylactic interventions to prevent life-threatening complications 1, 5, 3.